{"product_id":"glpg-vrio-analysis","title":"Galapagos NV (GLPG): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Galapagos NV (GLPG) truly built to last? This VRIO analysis cuts straight to the core, rigorously testing whether its Value, Rarity, Inimitability, and Organization combine to forge an unshakeable competitive advantage. Dive in now to uncover the definitive verdict on its market strength and what it means for its future success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 1. Substantial Cash Reserves and Financial Flexibility\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at a company in a major pivot, and the first thing that jumps out is the sheer size of the war chest they’ve built up. Honestly, this cash position is the bedrock of the entire new strategy at Galapagos NV. It gives leadership the breathing room to make big, transformative moves without the immediate pressure of a looming funding gap.\u003c\/p\u003e\n\u003cp\u003eAs of September 30, 2025, Galapagos NV held €3.05 billion in cash and financial investments. That’s a massive number in the biotech space, especially after they took the hit from restructuring and the decision to wind down the cell therapy operations announced in October 2025. Management projects the year-end 2025 cash position will settle between €2.975 billion and €3.025 billion, excluding any new business development spending or currency swings. That’s a defintely solid buffer.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on what that pile of cash is doing for them right now. It’s not just sitting there, either; it’s earning money. For the first nine months of 2025, the fair value gains and interest income from these assets hit €77.2 million. That’s capital working for the company while they hunt for the next big thing.\u003c\/p\u003e\n\u003cp\u003eThe current leadership, under CEO Henry Gosebruch, is explicitly organized around deploying this capital wisely. They are focused on disciplined stewardship and finding value-accretive transactions, prioritizing small molecule and biologics programs in immunology and oncology that have some proof-of-concept already. This structure is designed to translate that balance sheet strength into pipeline growth.\u003c\/p\u003e\n\u003cp\u003eThis cash position is a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e because it underpins every strategic decision they are making now. It buffers against the inherent R\u0026amp;D execution risk that plagues most biotechs. It’s not something a competitor can replicate overnight; it’s the result of past deals and recent strategic capital preservation.\u003c\/p\u003e\n\u003cp\u003eTo put the scale in context, here is a snapshot of the financial strength as of the end of Q3 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (as of Sept 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Financial Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€3.05 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRobust balance sheet following cell therapy review\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€46\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRepresents the value backing each share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Year-End 2025 Cash\u003c\/td\u003e\n\u003ctd\u003e€2.975B to €3.025B\u003c\/td\u003e\n\u003ctd\u003eExcluding new business development activities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest\/Fair Value Income (9M 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€77.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncome generated from the cash holdings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe rarity of this financial standing in the current biotech climate is notable. While they are winding down a major part of their former focus, the remaining entity has the firepower to be an acquirer or a major investor, rather than just a dependent researcher. This financial muscle makes them a serious player in deal-making.\u003c\/p\u003e\n\u003cp\u003eHere’s what this resource allows Galapagos NV to do strategically:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFund operations well into the future.\u003c\/li\u003e\n\u003cli\u003ePursue transformative, value-accretive deals.\u003c\/li\u003e\n\u003cli\u003eMaintain disciplined capital stewardship.\u003c\/li\u003e\n\u003cli\u003eDiversify risk across new programs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 2. Restructured Gilead Collaboration \u0026amp; Deferred Income\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a stable, non-dilutive revenue stream and strategic advantage through the ongoing Option, License and Collaboration Agreement (OLCA).\u003c\/p\u003e\n\u003cp\u003eThe deferred income balance related to the drug discovery platform was \u003cstrong\u003e€896.4 million\u003c\/strong\u003e at September 30, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeferred Income (Drug Discovery Platform)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€896.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Recognition (Discovery Platform)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€172.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst nine months of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeferred Income (Drug Discovery Platform)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€1.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJyseleca® Royalty Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€8.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst nine months of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific terms and long-standing nature of the relationship with a major player like Gilead are unique. The initial 2019 agreement included an upfront payment of \u003cstrong\u003e$3.95 billion\u003c\/strong\u003e (€3,569.8 million) and a \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e (€960.1 million) equity investment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Highly inimitable due to the contractual lock-in and the history embedded in the agreement, despite recent restructuring which returned development rights for legacy assets. Gilead retains an ownership stake of approximately \u003cstrong\u003e25%\u003c\/strong\u003e in the legacy Galapagos entity post-restructuring.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization is structured to manage the remaining obligations and leverage the partnership for new opportunities, as evidenced by the recent corporate split into two entities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLegacy Galapagos entity retains cell therapy pipeline and the remaining portion of the deferred income.\u003c\/li\u003e\n\u003cli\u003eThe new entity launched with \u003cstrong\u003e€2.45 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$2.53 billion\u003c\/strong\u003e) in cash for business development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as the contractual relationship is a sunk cost for Gilead and a guaranteed asset for Galapagos through ongoing revenue recognition from the deferred income balance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 3. GLPG5101 (CD19 CAR-T) Clinical Program Momentum\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePivotal development for GLPG5101 is planned to start following topline data expected in \u003cstrong\u003e2026\u003c\/strong\u003e. The program is being advanced by Galapagos Cell Therapeutics, a standalone entity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAttrition rate observed at \u003cstrong\u003e5%\u003c\/strong\u003e, compared to industry benchmarks up to \u003cstrong\u003e30%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e95%\u003c\/strong\u003e of patients were infused with fresh, stem-like early memory CD19 CAR-T cells.\u003c\/li\u003e\n\u003cli\u003eMedian vein-to-vein time achieved was \u003cstrong\u003e7 days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific clinical data and trial design are unique to Galapagos, although the underlying CAR-T technology is not entirely proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe establishment of Galapagos Cell Therapeutics as a standalone entity focuses organizational resources entirely on advancing this program. The company reported \u003cstrong\u003e€3.1 billion\u003c\/strong\u003e (or \u003cstrong\u003e$3.6 billion\u003c\/strong\u003e) in cash and financial investments at the end of June 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, contingent on future trial results, but currently strong due to early positive signals, with a goal for first approval by \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey ATALANTA-1 Clinical Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Enrolled (ATALANTA-1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal patients enrolled for one data cut.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Treated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatients who received treatment from the 64 enrolled.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAttrition Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCalculated rate based on enrolled vs. treated.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFresh Cell Infusion Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e95%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePercentage of treated patients receiving fresh product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Vein-to-Vein Time\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMedian time for fresh cell delivery.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget First Approval Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2028\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStated company goal.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 4. Decentralized Manufacturing Unit (DMU) Network\n\u003c\/h2\u003e\n\n\u003cp\u003eThe DMU Network operational and financial context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Partner\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Vein-to-Vein Time\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDelivery of fresh, early-memory cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLPG5101 Infusion within 7 Days (ATALANTA-1)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eOut of those assessed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Treated within 7 Days (Pooled Data)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e89%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOf 64 patients enrolled in a cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Partner (France)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCELLforCURE by SEQENS\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLes Ulis facility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Manufacturing Expansion Partners\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBlood Centers of America\u003c\/strong\u003e, \u003cstrong\u003eLandmark Bio\u003c\/strong\u003e, \u003cstrong\u003eThermo Fisher Scientific\u003c\/strong\u003e, \u003cstrong\u003eCatalent\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisitions for Capability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCellPoint\u003c\/strong\u003e \u0026amp; \u003cstrong\u003eAbound Bio\u003c\/strong\u003e in \u003cstrong\u003e2022\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEnd-to-end capabilities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€3.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (H1 2025, continuing ops)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€215.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe platform is designed to deliver fresh, stem-like, early memory cells with a vein-to-vein time of \u003cstrong\u003eseven days\u003c\/strong\u003e. The platform supports the delivery of GLPG5101 with \u003cstrong\u003e89%\u003c\/strong\u003e of patients receiving treatment within \u003cstrong\u003eseven days\u003c\/strong\u003e in a pooled data set. The ATALANTA-1 study showed \u003cstrong\u003e23\u003c\/strong\u003e patients infused within a week of collection.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA fully operational, validated decentralized manufacturing network for autologous cell therapy is rare among biotechs of this scale. The platform consists of an end-to-end xCellit® workflow management system, an automated manufacturing platform (using Lonza's Cocoon®), and proprietary quality control testing. The capability was established via acquisitions of \u003cstrong\u003eCellPoint\u003c\/strong\u003e and \u003cstrong\u003eAbound Bio\u003c\/strong\u003e in \u003cstrong\u003e2022\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eVery difficult to imitate; requires massive capital investment, regulatory navigation, and specialized operational expertise. Subcontracting costs related to cell therapy programs increased by \u003cstrong\u003e€77.1 million\u003c\/strong\u003e from \u003cstrong\u003e€83.0 million\u003c\/strong\u003e in 2023 to \u003cstrong\u003e€160.1 million\u003c\/strong\u003e in the first six months of 2024. The company reported a cash position of \u003cstrong\u003e€3.3 billion\u003c\/strong\u003e at the end of 2024. Partnerships include \u003cstrong\u003eCELLforCURE by SEQENS\u003c\/strong\u003e in France and expansion partners in the U.S. including \u003cstrong\u003eCatalent\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe entire cell therapy strategy is built around exploiting this platform for speed and efficiency. The company's cash and current financial investments as of June 30, 2024, totaled \u003cstrong\u003e€3.4304 billion\u003c\/strong\u003e. The company reported total operating loss from continuing operations for the six months ended June 30, 2025, at \u003cstrong\u003e€215.7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, provided the regulatory pathway remains favorable and the operational execution is flawless. The company's cash position as of June 30, 2025, was \u003cstrong\u003e€3.1 billion\u003c\/strong\u003e. The average analyst target price for GLPG was \u003cstrong\u003e$26.97\u003c\/strong\u003e based on 5 analysts.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 5. Focused Business Development (BD) Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Following the strategic review, the organization is now explicitly focused on disciplined capital stewardship and executing transformational transactions to build the pipeline. The strategic review concluded with an intention to wind down the cell therapy business to support a stronger and sustainable future for Galapagos. The company reported a strong balance sheet with €3.1 billion in cash and financial investments as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The recent recruitment of seasoned business development leaders signals a dedicated, high-level organizational shift that is rare for a company undergoing such a major internal reorganization. Key appointments include Sooin Kwon as Chief Business Officer (CBO) and Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025. Furthermore, the Board of Directors was strengthened with appointments bringing business development expertise.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The team and mandate are new, but the capability to execute deals is something competitors can build. The costs associated with the strategic reorganization and intended separation in the first half of 2025 totaled €131.6 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The entire corporate structure is being realigned to support this BD-first approach for the non-cell therapy assets\/future acquisitions. This realignment is evidenced by the leadership evolution and the decision to explore strategic alternatives for the cell therapy business to maximize resources for transformative BD transactions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the success hinges on the quality and timing of the first few deals. The capacity to pursue these deals is underpinned by significant financial resources and new leadership.\u003c\/p\u003e\n\u003cp\u003eKey quantitative metrics supporting the Focused BD Capability:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Category\u003c\/td\u003e\n\u003ctd\u003eSpecific Data Point\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Capacity (H1 2025)\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents and financial investments (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€3.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Capacity (Forecast)\u003c\/td\u003e\n\u003ctd\u003eExpected year-end 2025 cash position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€2.975 billion to €3.025 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeadership Appointment (Executive)\u003c\/td\u003e\n\u003ctd\u003eChief Business Officer (CBO) Appointment Date\u003c\/td\u003e\n\u003ctd\u003eAugust 4, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeadership Appointment (Board)\u003c\/td\u003e\n\u003ctd\u003eBoard Director Appointment Date (Devang Bhuva, SVP Corp Dev at Gilead)\u003c\/td\u003e\n\u003ctd\u003eNovember 1, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Transaction Support\u003c\/td\u003e\n\u003ctd\u003eConvertible loan facility for assets sold to Onco3R Therapeutics BV\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Reorganization Cost\u003c\/td\u003e\n\u003ctd\u003eTotal costs for strategic reorganization and intended separation (H1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€131.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational shift is further detailed by specific leadership roles created or appointed to drive this strategy:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAppointment of Sooin Kwon as Chief Business Officer (CBO).\u003c\/li\u003e\n\u003cli\u003eAppointment of Dan Grossman as Chief Strategy Officer (CStO).\u003c\/li\u003e\n\u003cli\u003eAppointment of Devang Bhuva, Senior Vice President of Corporate Development and Alliance Management at Gilead, to the Board of Directors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial foundation for this strategy is derived from the planned separation, where the new entity (SpinCo) was initially intended to be capitalized with approximately €2.45 billion in cash. The original Gilead Option, License and Collaboration Agreement (OLCA) involved an upfront payment of $3.95 billion and a $1.1 billion equity investment.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 6. GLPG3667 (Oral TYK2 Inhibitor) Late-Stage Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This small molecule asset is in Phase 3-enabling studies for SLE and DM, with topline data expected in H1 2026, positioning it as a potential best-in-class opportunity in a market projected to exceed \u003cstrong\u003e$3.0 billion\u003c\/strong\u003e by 2030.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having a late-stage, potentially best-in-class asset in a growing market segment is valuable, even if the company is seeking a partner.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific molecule and its development data are unique, but the therapeutic class (TYK2 inhibitors) is competitive.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively seeking partners to take this forward, showing an organized approach to monetizing non-core assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the value is locked until the data is released and a deal is signed.\u003c\/p\u003e\n\u003cp\u003eThe asset's current development status and differentiation profile are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Stage\u003c\/td\u003e\n\u003ctd\u003ePhase 3-enabling studies for SLE (GALACELA) and DM (GALARISSO)\u003c\/td\u003e\n\u003ctd\u003ePhase 3-enabling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTopline Data Anticipation\u003c\/td\u003e\n\u003ctd\u003eEntire GLPG3667 program\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eH1 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLE Study Dosing (GALACELA)\u003c\/td\u003e\n\u003ctd\u003eOnce-daily oral GLPG3667 (\u003cstrong\u003e75 mg\u003c\/strong\u003e and \u003cstrong\u003e150 mg\u003c\/strong\u003e) or placebo\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e140\u003c\/strong\u003e adult patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDM Study Dosing (GALARISSO)\u003c\/td\u003e\n\u003ctd\u003eOnce-daily oral GLPG3667 \u003cstrong\u003e150 mg\u003c\/strong\u003e or placebo\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e62\u003c\/strong\u003e adult patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn Vitro Differentiation (IL-10)\u003c\/td\u003e\n\u003ctd\u003eNo measurable inhibition of IL-10-mediated signaling\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e~10-fold\u003c\/strong\u003e above clinical concentrations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Landscape (Approved)\u003c\/td\u003e\n\u003ctd\u003eOnly approved TYK2 inhibitor (SOTYKTU) US market size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUSD 190 million\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Landscape (Growth)\u003c\/td\u003e\n\u003ctd\u003eSOTYKTU US market year-over-year increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's financial position supports the ongoing development and partnership search:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and current financial investments as of \u003cstrong\u003e31 December 2023\u003c\/strong\u003e: \u003cstrong\u003e€3.7 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company is seeking potential partners to take over small molecule assets, including GLPG3667.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 7. Intellectual Property on Drug Discovery Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This is the core IP that generated the significant upfront and milestone payments from Gilead, evidenced by the \u003cstrong\u003e€1.0 billion\u003c\/strong\u003e deferred income balance as of June 30, 2025, allocated to the drug discovery platform under the OLCA. The revenue recognition related to the exclusive access rights granted to Gilead for the platform amounted to \u003cstrong\u003e€115.1 million\u003c\/strong\u003e for the first six months of both 2025 and 2024. The initial transaction included a \u003cstrong\u003e$3.95 billion\u003c\/strong\u003e upfront payment and a \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e equity investment from Gilead.\u003c\/p\u003e\n\u003cp\u003eThe financial structure supporting the platform's value is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeferred Income (Platform Allocation)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€1.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Recognized (Platform Access)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€115.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025 and 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Upfront Payment (Gilead Deal)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.95 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Equity Investment (Gilead Deal)\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e (or \u003cstrong\u003e€960 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eAugust 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The platform itself, which underpinned the original massive Gilead deal, represents years of proprietary research and discovery methods.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe proprietary drug discovery platform includes a Target discovery platform with \u003cstrong\u003e5.4 million compounds\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's research capabilities are supported by a large patent portfolio; one report indicates \u003cstrong\u003e544 patent families\u003c\/strong\u003e protecting innovations as of a recent assessment.\u003c\/li\u003e\n\u003cli\u003eGalapagos' grant share, based on the ratio of grants to total patents, was reported at \u003cstrong\u003e38%\u003c\/strong\u003e as of July 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The fundamental science is protected by patents, making direct imitation of the core technology difficult.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe core technology includes granted patents protecting the adenoviral gene knock-down (SilenceSelect®) and gene knock-in (FLeXSelect®) collections, with issuances dating back to at least \u003cstrong\u003e2005\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSpecific product candidates derived from the platform, such as GLPG3667, have patent protection including at least \u003cstrong\u003eone granted U.S. patent\u003c\/strong\u003e and \u003cstrong\u003eone granted European Patent Office (EPO) patent\u003c\/strong\u003e as of March 1, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP is effectively ring-fenced and monetized via the Gilead OLCA, showing effective management of this asset.\u003c\/p\u003e\n\u003cp\u003eThe management of the IP is evidenced by:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eThe 10-year global Option, License and Collaboration Agreement (OLCA) with Gilead Sciences, which grants Gilead access to the platform.\u003c\/li\u003e\n\u003cli\u003eThe recent amendment to the OLCA, where Galapagos regained full global development and commercialization rights to its pipeline, subject to paying Gilead \u003cstrong\u003esingle digit royalties\u003c\/strong\u003e on net sales of certain products.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the underlying patents remain in force.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 8. Asset Recycling\/Divestiture Execution\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe demonstrated ability to execute a strategic sale and financing agreement, such as the April 2025 deal with Onco3R Therapeutics for small molecule assets, including a \u003cstrong\u003e€20 million\u003c\/strong\u003e convertible loan facility. This action frees up capital and focuses resources.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnco3R Convertible Loan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancing agreement for small molecule asset sale (April 2025).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Financial Investments (H1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€3,091.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Financial Investments (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€3.05 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 Restructuring Costs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€131.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCosts for strategic reorganization and intended separation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 Deal Costs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€16.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluded in H1 2025 restructuring costs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2024 Operating Profit (Discontinued Ops)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€52.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGain on sale of Jyseleca® business to Alfasigma.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe speed and decisiveness in divesting non-core assets post-restructuring announcement (January 2025 announcement) is a sign of organizational agility, evidenced by the April 2025 Onco3R agreement.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nSmall molecule discovery programs discontinued following the January 2025 announcement.\n\u003c\/li\u003e\n\u003cli\u003e\nStrategic review concluded with intention to wind down cell therapy business announced October 21, 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitors can execute similar deals, but Galapagos showed a clear, rapid process in 2025 following the strategic shift.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nThe company incurred \u003cstrong\u003e€45.7 million\u003c\/strong\u003e in costs for early termination of collaborations in the first half of 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe new leadership, appointed with seasoned business development leaders, is clearly organized to repeat this capital recycling process, focusing on disciplined capital stewardship.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nNew CEO, CFO, and business development leaders joined in the first half of 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nExpected to be cash flow neutral to positive by the end of \u003cstrong\u003e2026\u003c\/strong\u003e, excluding business development activities.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary, as it is an action, not a static resource, but it sets a precedent for future transactions that maximize cash available for business development.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGalapagos NV (GLPG) - VRIO Analysis: 9. Leadership Experience in Strategic Transformation\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The current leadership team, including the new CEO, has a proven track record in executing major corporate restructurings and driving growth in specialized therapeutic areas.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific combination of leaders with deep pharma\/biotech operational and BD experience is not common, defintely.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Leadership experience is hard to copy; it is built over decades of careers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The entire strategic pivot in 2025 - from the proposed split to the focus on cell therapy and BD - is a direct result of this leadership's vision and execution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as this team remains in place and aligned.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLeadership Team Experience Highlights:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHenry Gosebruch, appointed CEO of Galapagos effective May 13, 2025, previously served as CEO of Neumora and held senior positions at AbbVie and J.P. Morgan.\u003c\/li\u003e\n\u003cli\u003eThe initial plan involved Gosebruch as Founding CEO of the planned SpinCo, which was to be funded with approximately €2.45 billion in cash.\u003c\/li\u003e\n\u003cli\u003eNew appointments include Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer, both possessing proven track records in strategic execution and deal-making.\u003c\/li\u003e\n\u003cli\u003eThe strategic review concluded with an intention to wind down the cell therapy business.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinancial Context Supporting Strategic Execution:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Financial Investments\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e€3.0501 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Financial Investments\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately €3.1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Financial Investments\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003ctd\u003e€3.2973 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Financial Investments\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e€3.3178 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Year-End 2025 Cash Position\u003c\/td\u003e\n\u003ctd\u003eEnd of 2025\u003c\/td\u003e\n\u003ctd\u003e€2.975 billion to €3.025 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNormalized Annual Cash Burn (Excl. Restructuring)\u003c\/td\u003e\n\u003ctd\u003eGuidance\u003c\/td\u003e\n\u003ctd\u003e€175 million to €225 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Decrease in Cash (First Six Months 2025)\u003c\/td\u003e\n\u003ctd\u003eH1 2025\u003c\/td\u003e\n\u003ctd\u003e€226.3 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Cash Burn (First Six Months 2025)\u003c\/td\u003e\n\u003ctd\u003eH1 2025\u003c\/td\u003e\n\u003ctd\u003e€91.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eFirst Nine Months 2025\u003c\/td\u003e\n\u003ctd\u003e€461.3 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenues\u003c\/td\u003e\n\u003ctd\u003eFirst Nine Months 2025\u003c\/td\u003e\n\u003ctd\u003e€211.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe latest reported cash position as of September 30, 2025, was €3.0501 billion. The year-end 2025 cash position is anticipated to be between €2.975 billion and €3.025 billion.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516173246613,"sku":"glpg-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/glpg-vrio-analysis.png?v=1740176550","url":"https:\/\/dcf-model.com\/pt\/products\/glpg-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}